Results 121 to 130 of about 195,924 (307)
The addition of bevacizumab to standard chemotherapy in breast cancer : which patient benefits the most? [PDF]
Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is an effective and well-tolerated treatment option for patients with breast cancer.
Cocquyt, Veronique +4 more
core +2 more sources
FAK signaling drives chemoresistance and tumor evolution in pancreatic ductal adenocarcinoma. The FAK inhibitor IN10018 restores gemcitabine sensitivity by inducing SLC7A11‐mediated ferroptosis through the PI3K‐Akt pathway and remodeling the tumor microenvironment, reducing mesenchymal components while enhancing CD8+ T‐cell infiltration in preclinical ...
Yingjin Wang +11 more
wiley +1 more source
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. [PDF]
Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune responses ...
Arrillaga-Romany, Isabel C +29 more
core
Australia cohort of THASSOS‐INTL; non‐interventional, multicenter, retrospective study provides insights into treatment patterns and associated survival outcomes in patients with resectable stage I‐III NSCLC in the pre‐immunotherapy era. Neoadjuvant and adjuvant therapy was reported in < 10% and < 40% patients, respectively.
Pei Ding +4 more
wiley +1 more source
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund +4 more
wiley +1 more source
Laparoscopic Colorectal Surgery in the Era of Robotics: Evolution, Eclipse, or Equilibrium?
ABSTRACT Minimally invasive colorectal surgery has undergone a remarkable transformation over the past three decades. Laparoscopy, once viewed with skepticism, is now firmly established as a standard approach, supported by robust randomized trials demonstrating oncologic safety and improved recovery compared to open surgery.
Amanjeet Singh +3 more
wiley +1 more source
All patients operated for oesophageal cancer in Sweden from 2013 to April 2018 were identified, and 246 patients were recruited to this population‐based nationwide Swedish study. The results show that longitudinal health‐related quality of life after minimally invasive oesophagectomy was similar to that of the open surgical approach.
F. Klevebro +4 more
wiley +1 more source
ABSTRACT Background Robot‐assisted rectal surgery (RAS) offers improved dexterity and visualization; however, the high cost of equipment and consumables remains a major challenge for hospital management. At our institution, we have adopted a combined approach using transanal total mesorectal excision (TaTME) for lower rectal cancers, aiming to shorten ...
Takeru Matsuda +9 more
wiley +1 more source
NAT‐GS was significantly more effective only in patients with one tumor marker above the reference range, comparing those who achieved 12‐month MRFS with those who did not. ABSTRACT Aim Pancreatic cancer (PC) remains one of the most lethal malignancies, with early recurrence severely affecting prognosis even after curative resection.
Hiromichi Kawaida +9 more
wiley +1 more source
In advanced colorectal cancer, tumors with mature tertiary lymphoid structures (TLS) exhibited abundant infiltration of CD3‐ and CD8‐positive lymphocytes in both primary and metastatic sites, indicating an activated immune response. The presence of mature TLS was also associated with favorable chemotherapy sensitivity and improved prognosis.
Nobuhiro Hosoi +9 more
wiley +1 more source

